Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Congenital enteropathy due to enteropeptidase deficiency
Congenital enteropathy due to enteropeptidase deficiency
Congenital enteropathy due to enteropeptidase deficiency
Synonyms: Congenital enterokinase deficiency
Synonyms: Congenital enterokinase deficiency
Synonyms: Congenital enterokinase deficiency
Drug discovery
14
papers
On emerging therapies
Rare gastroenterologic diseases
Congenital enteropathy due to enteropeptidase deficiency
Overview
Congenital enteropathy due to enteropeptidase deficiency is a rare, autosomal recessive disorder caused by TMPRSS15 mutations, disrupting enteropeptidase enzyme production critical for activating pancreatic proteases [1][5][19]. It manifests in infancy with failure to thrive, hypoproteinemia, edema, chronic diarrhea, and fat malabsorption [1][2][15]. Diagnosis relies on reduced duodenal trypsin activity and genetic testing. Treatment involves hydrolyzed formulas or pancreatic enzyme supplementation to bypass defective protease activation [3][5][6].
Burden
High morbidity from chronic malnutrition, hypoalbuminemia-related edema, and growth delays. Lifelong dietary management is often required, with risks of developmental impairment and recurrent infections [1][2][15]. Limited awareness and diagnostic delays exacerbate healthcare costs and caregiver burden [6][9].
Therapies
Hydrolyzed protein formulas (elemental or extensively hydrolyzed) to prevent malnutrition [3][6][7].
Pancreatic enzyme replacement (e.g., enterokinase supplements) to restore digestive function [5][19].
Nutritional support with albumin infusions, electrolyte management, and fat-soluble vitamin supplementation [3][6][15].
Categories: rare gastroenterological diseases, rare genetic diseases
Research Papers
14 drug discovery papers about Congenital enteropathy due to enteropeptidase deficiency. Recent publications:
14 drug discovery papers about Congenital enteropathy due to enteropeptidase deficiency. Recent publications:
categories:
Small molecules
proteins
2025-01-29 | Enterokinase deficiency associated with novel TMPRSS15 gene mutations: a case report
Background Enterokinase deficiency (EKD,OMIM #226200) is a rare autosomal recessive genetic disorder caused by mutations in transmembrane protease serine 15 (TMPRSS15). Herein, we report a case of EKD in a patient with novel compound heterozygous TMPRSS15 mutations. Case presentation A 2-month-old female infant presented with chronic diarrhea, vomiting, pallor, general edema, skin lesions, and a failure to gain weight. Further examination revealed anemia, hypoalbuminemia, and multiorgan damage. Whole-exome sequencing further revealed two novel heterozygous variants of TMPRSS15: c.2611C>T (p.Arg871Ter) and c.1584_1585insCTTT (p.Glu529LeufsTer2). The clinical symptoms dramatically improved following pancreatic enzyme replacement. During a one-year follow-up, the patient showed a normal rate of physical development, with no recurrence of anemia, hypoproteinemia, coagulopathy or skin lesions. Conclusion Herein, we presented a clinical case of EKD with two novel compound heterozygous mutations in TMPRSS15 who achieved dramatic symptom improvements following pancreatic enzyme supplementation. This case enriches the genotypic spectrum of EKD and provides a reference for the diagnosis and treatment of similar cases. This case suggests that if zymogen activation testing is not possible, genetic analysis may be an effective tool to facilitate early diagnosis. Further, early pancreatic enzyme supplementation is a clinical strategy which can achieve satisfactory outcomes.
2013-10-30 | Do-it-yourself histidine-tagged bovine enterokinase: A handy member of the protein engineer's toolbox
Enterokinase, a two-chain duodenal serine protease, activates trypsinogen by removing its N-terminal propeptide. Due to a clean cut after the non-primed site recognition sequence, the enterokinase light chain is frequently employed in biotechnology to separate N-terminal affinity tags from target proteins with authentic N-termini. In order to obtain large quantities of this protease, we adapted an in vitro folding protocol for a pentahistidine-tagged triple mutant of the bovine enterokinase light chain. The purified, highly active enzyme successfully processed recombinant target proteins, while the pentahistidine-tag facilitated post-cleavage removal. Hence, we conclude that producing enterokinase in one's own laboratory is an efficient alternative to the commercial enzyme.
2011-08-25 | High level expression of human enteropeptidase light chain in Pichia pastoris
Human enterokinase (enteropeptidase, rhEP), a serine protease expressed in the proximal part of the small intestine, converts the inactive form of trypsinogen to active trypsin by endoproteolytic cleavage. The high specificity of the target site makes enterokinase an ideal tool for cleaving fusion proteins at defined cleavage sites. The mature active enzyme is comprised of two disulfide-linked polypeptide chains. The heavy chain anchors the enzyme in the intestinal brush border membrane, whereas the light chain represents the catalytic enzyme subunit. The synthetic gene encoding human enteropeptidase light chain with His-tag added at the C-terminus to facilitate protein purification was cloned into Pichia pastoris expression plasmids under the control of an inducible AOX1 or constitutive promoters GAP and AAC. Cultivation media and conditions were optimized as well as isolation and purification of the target protein. Up to 4 mg/L of rhEP was obtained in shake-flask experiments and the expression level of about 60-70 mg/L was achieved when cultivating in lab-scale fermentors. The constitutively expressing strains proved more efficient and less labor-demanding than the inducible ones. The rhEP was immobilized on AV 100 sorbent (Iontosorb) to allow repeated use of enterokinase, showing specific activity of 4U/mL of wet matrix.
1988-01-01 | Long-Term Pancreatic-Biliary Diversion in the Rat: Persistent Loss of Mucosal Enterokinase, with Reinduction by Delayed Oral Pancreatic Biliary Supplementation
Diversion of pancreatic-biliary (PB) secretions in rats for 23 days led to loss of enterokinase (EK) activity in bypassed segments of the small intestine. Simultaneous oral trypsinogen and bile salt (TB) supplements prevented the loss of EK activity. To study the temporal course of events after PB diversion and to determine if the loss of EK is reversible, PB diversion was performed in rats by surgical transposition of the 4-cm segment of duodenum including the ampulla of Vater to a point 30 cm distal to its original site. Bypassed and control (sham- and nonoperated) rats fed standard rat chow were sacrificed at 10, 23, and 45 days after surgery. One bypassed group was fed standard chow for 23 days and then chow supplemented with TB until sacrifice at 45 days. At sacrifice, the intestines were divided into segment 1 (the bypassed proximal 30 cm) and segment 2 (the 30 cm distal to the bypass). In segment 1, EK disappeared almost completely by 10 days and remained at the same low levels at both 23 and 45 days (p less than 0.05). No significant changes in EK levels were found at any time in segment 2 distal to the bypass. Mucosal disaccharidase activity in segment 1 increased or showed no change. In rats with delayed TB supplementation, EK activity in segment 1 returned almost to control levels at the time of sacrifice. The results confirm the importance of PB secretions in the maintenance of EK activity. The effects of bypass on EK are both enzyme- and site-specific.(ABSTRACT TRUNCATED AT 250 WORDS)
1986-05-01 | Small Intestinal Mucosal Hyperplasia Caused by an Enterokinase Inhibitor from Red Kidney Bean in Rats
A specific enterokinase inhibitor (EKI) was purified from red kidney bean (RKB). Male weanling rats fed a diet containing this purified EKI (0.06%) for 6 d showed increases in mucosal weights, protein, DNA and lactic dehydrogenase contents in their small intestines compared to age-matched control rats fed a standard diet. Total mucosal EK and disaccharidase activities were, however, decreased in EKI-fed rats. Thus, oral consumption of EKI from RKB led to small intestinal mucosal hyperplasia in rats. The mucosal hyperplasia observed in EKI-fed rats is not likely due to decreased turnover of mucosal proteins as a result of reduced luminal proteases since luminal contents of trypsin, chymotrypsin and elastase in EKI-fed rats were similar to those of control rats. Enterokinase inhibitor may have a direct hyperplastic effect on the small intestine of rats.
proteins
2025-01-29 | Enterokinase deficiency associated with novel TMPRSS15 gene mutations: a case report
Background Enterokinase deficiency (EKD,OMIM #226200) is a rare autosomal recessive genetic disorder caused by mutations in transmembrane protease serine 15 (TMPRSS15). Herein, we report a case of EKD in a patient with novel compound heterozygous TMPRSS15 mutations. Case presentation A 2-month-old female infant presented with chronic diarrhea, vomiting, pallor, general edema, skin lesions, and a failure to gain weight. Further examination revealed anemia, hypoalbuminemia, and multiorgan damage. Whole-exome sequencing further revealed two novel heterozygous variants of TMPRSS15: c.2611C>T (p.Arg871Ter) and c.1584_1585insCTTT (p.Glu529LeufsTer2). The clinical symptoms dramatically improved following pancreatic enzyme replacement. During a one-year follow-up, the patient showed a normal rate of physical development, with no recurrence of anemia, hypoproteinemia, coagulopathy or skin lesions. Conclusion Herein, we presented a clinical case of EKD with two novel compound heterozygous mutations in TMPRSS15 who achieved dramatic symptom improvements following pancreatic enzyme supplementation. This case enriches the genotypic spectrum of EKD and provides a reference for the diagnosis and treatment of similar cases. This case suggests that if zymogen activation testing is not possible, genetic analysis may be an effective tool to facilitate early diagnosis. Further, early pancreatic enzyme supplementation is a clinical strategy which can achieve satisfactory outcomes.
2013-10-30 | Do-it-yourself histidine-tagged bovine enterokinase: A handy member of the protein engineer's toolbox
Enterokinase, a two-chain duodenal serine protease, activates trypsinogen by removing its N-terminal propeptide. Due to a clean cut after the non-primed site recognition sequence, the enterokinase light chain is frequently employed in biotechnology to separate N-terminal affinity tags from target proteins with authentic N-termini. In order to obtain large quantities of this protease, we adapted an in vitro folding protocol for a pentahistidine-tagged triple mutant of the bovine enterokinase light chain. The purified, highly active enzyme successfully processed recombinant target proteins, while the pentahistidine-tag facilitated post-cleavage removal. Hence, we conclude that producing enterokinase in one's own laboratory is an efficient alternative to the commercial enzyme.
2011-08-25 | High level expression of human enteropeptidase light chain in Pichia pastoris
Human enterokinase (enteropeptidase, rhEP), a serine protease expressed in the proximal part of the small intestine, converts the inactive form of trypsinogen to active trypsin by endoproteolytic cleavage. The high specificity of the target site makes enterokinase an ideal tool for cleaving fusion proteins at defined cleavage sites. The mature active enzyme is comprised of two disulfide-linked polypeptide chains. The heavy chain anchors the enzyme in the intestinal brush border membrane, whereas the light chain represents the catalytic enzyme subunit. The synthetic gene encoding human enteropeptidase light chain with His-tag added at the C-terminus to facilitate protein purification was cloned into Pichia pastoris expression plasmids under the control of an inducible AOX1 or constitutive promoters GAP and AAC. Cultivation media and conditions were optimized as well as isolation and purification of the target protein. Up to 4 mg/L of rhEP was obtained in shake-flask experiments and the expression level of about 60-70 mg/L was achieved when cultivating in lab-scale fermentors. The constitutively expressing strains proved more efficient and less labor-demanding than the inducible ones. The rhEP was immobilized on AV 100 sorbent (Iontosorb) to allow repeated use of enterokinase, showing specific activity of 4U/mL of wet matrix.
1988-01-01 | Long-Term Pancreatic-Biliary Diversion in the Rat: Persistent Loss of Mucosal Enterokinase, with Reinduction by Delayed Oral Pancreatic Biliary Supplementation
Diversion of pancreatic-biliary (PB) secretions in rats for 23 days led to loss of enterokinase (EK) activity in bypassed segments of the small intestine. Simultaneous oral trypsinogen and bile salt (TB) supplements prevented the loss of EK activity. To study the temporal course of events after PB diversion and to determine if the loss of EK is reversible, PB diversion was performed in rats by surgical transposition of the 4-cm segment of duodenum including the ampulla of Vater to a point 30 cm distal to its original site. Bypassed and control (sham- and nonoperated) rats fed standard rat chow were sacrificed at 10, 23, and 45 days after surgery. One bypassed group was fed standard chow for 23 days and then chow supplemented with TB until sacrifice at 45 days. At sacrifice, the intestines were divided into segment 1 (the bypassed proximal 30 cm) and segment 2 (the 30 cm distal to the bypass). In segment 1, EK disappeared almost completely by 10 days and remained at the same low levels at both 23 and 45 days (p less than 0.05). No significant changes in EK levels were found at any time in segment 2 distal to the bypass. Mucosal disaccharidase activity in segment 1 increased or showed no change. In rats with delayed TB supplementation, EK activity in segment 1 returned almost to control levels at the time of sacrifice. The results confirm the importance of PB secretions in the maintenance of EK activity. The effects of bypass on EK are both enzyme- and site-specific.(ABSTRACT TRUNCATED AT 250 WORDS)
1986-05-01 | Small Intestinal Mucosal Hyperplasia Caused by an Enterokinase Inhibitor from Red Kidney Bean in Rats
A specific enterokinase inhibitor (EKI) was purified from red kidney bean (RKB). Male weanling rats fed a diet containing this purified EKI (0.06%) for 6 d showed increases in mucosal weights, protein, DNA and lactic dehydrogenase contents in their small intestines compared to age-matched control rats fed a standard diet. Total mucosal EK and disaccharidase activities were, however, decreased in EKI-fed rats. Thus, oral consumption of EKI from RKB led to small intestinal mucosal hyperplasia in rats. The mucosal hyperplasia observed in EKI-fed rats is not likely due to decreased turnover of mucosal proteins as a result of reduced luminal proteases since luminal contents of trypsin, chymotrypsin and elastase in EKI-fed rats were similar to those of control rats. Enterokinase inhibitor may have a direct hyperplastic effect on the small intestine of rats.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.